The Pharma Data

AUGUST 16, 2021

Following the current preclinical development of CV2CoV, a Phase 1 clinical trial is expected to start in Q4 2021. CV2CoV was engineered with specifically optimized non-coding regions to exhibit improved mRNA translation for increased and extended protein expression compared the first-generation mRNA backbone.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

SEPTEMBER 10, 2020

OCREVUS is the first and only treatment approved for both relapsing MS (RMS) and primary progressive MS (PPMS) and now more than 170,000 people have been treated with OCREVUS globally in clinical trial and real-world settings; favourable benefit-risk profile remains consistent over 7 years. Separate data from a U.S.

Treatment 52

Treatment Disease FDA Approval Clinical Trials 52

The Anticancer Fund

SEPTEMBER 29, 2021

Please get in touch if you’re interested in discussing research based on the findings presented below ( info@anticancerfund.org ). This trial report shows that the treatment can be administered safely and there is an encouraging efficacy signal. All articles need to be critically assessed and viewed in their broader research context.

Clinical Trials 40

Clinical Trials Drugs Trials Protein Expression 40

Alta Sciences

APRIL 17, 2024

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

OCTOBER 28, 2020

Further detail from the first five patients will be presented at the Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit in December 2020. In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. About Angelman Syndrome.

Protein Expression 40

Protein Expression Therapies Treatment Disease 40

Codon

APRIL 14, 2025

Raising our expectations surrounding service providers presents another high-leverage opportunity for driving cultural change. One such opportunity, for example, is in protein expression. As a first step, they are collecting a large, diverse dataset of protein expression measurements in multiple widely-used microbial hosts.

Protein Expression 88

Protein Expression Engineering Research RNA 88

The Pharma Data

DECEMBER 3, 2020

Highlights from the Company’s presentations include: BUTTERFLY Observational Study – Baseline Analysis. Clinical Trials. A review of the study design for MONARCH, the Company’s ongoing Phase 1/2a study of STK-001 in children and adolescents with Dravet syndrome will be presented during a poster session by Linda Laux, M.D.,

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

The Pharma Data

SEPTEMBER 28, 2021

The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to 6 weeks aged and data supporting the continued clinical investigation of gene therapy, SRP-9001, in Duchenne dystrophy (DMD).

Clinical Trials 52

Clinical Trials Protein Expression Therapies FDA 52

The Pharma Data

JULY 21, 2021

(NYSE: PFE), today announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial builds on previous positive Phase 2 trials and includes both adult and pediatric participants with the aim to support acceleration of the vaccine candidate’s pediatric program.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

The Pharma Data

AUGUST 9, 2021

Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superiority over trastuzumab emtansine (T-DM1).

Trials 52

Trials Treatment Clinical Trials Protein Expression 52

The Pharma Data

APRIL 27, 2022

Targeting the lower range of expression in the HER2 spectrum may offer another approach to delay disease progression and extend survival in patients with metastatic breast cancer. The FDA granted the BTD based on data from the pivotal DESTINY-Breast04 Phase III trial which reported positive high-level results in February 2022.

Therapies 52

Therapies Trials Protein Expression Treatment 52

The Pharma Data

JANUARY 15, 2021

In the DESTINY-Gastric01 trial, patients (n=126) in the Enhertu treatment arm had a 41% reduction in the risk of death versus patients (n=62) treated with chemotherapy (based on a hazard ratio [HR] of 0.59; 95% confidence interval [CI] 0.39-0.88; Regular approval by the U.S. months [95% CI 9.6-14.3] months [95% CI 6.9-10.7] with chemotherapy.

Treatment 52

Treatment Trials Disease Therapies 52

Conversations in Drug Development Trends

MAY 30, 2024

Authors: Rich Worldwide Clinical Trials Exec. This trend is on the rise despite recent disappointments with clinical trial outcomes, which have the potential to destabilize the industry in the short term regarding drug development strategy and optimal study designs. Director, Therapeutic Area Medical Lead.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

The Pharma Data

JANUARY 13, 2021

However, before the Phase III program may begin, the FDA requested a meeting with Theratechnologies to discuss questions and comments received on certain aspects of the proposed trial design, to ensure alignment with the agency’s expectations with NASH trials. A second liver biopsy will be performed after 18 months.

Licensing 52

Licensing Licensing Clinical Trials Vaccine 52

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. Key findings of the trial: .

Vaccine 40

Vaccine Trials Treatment Virus 40

Conversations in Drug Development Trends

APRIL 7, 2025

Solid tumors present a significant challenge to clinical research due to their complex and heterogeneous nature. Have you optimized your trial designs to employ precision medicine approaches for your novel solid tumor intervention?

Research 40

Research Clinical Trials Trials Clinical Research 40